Related Experiment Video
Updated: Oct 6, 2025
Clinical Protocol of Producing Adipose Tissue-Derived Stromal Vascular Fraction for Potential Cartilage Regeneration
Published on: September 29, 2018
Engineered adipose-derived stem cells with IGF-1-modified mRNA ameliorates osteoarthritis development
Haoyu Wu1,2,3, Zhi Peng1,3, Ying Xu1,3
1Dr. Li Dak Sum & Yip Yio Chin Center for Stem Cells and Regenerative Medicine, and Department of Orthopedic Surgery of the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310058, China.
Engineered adipose-derived stem cells (ADSCs) using modified mRNA (modRNA) to express insulin-like growth factor 1 (IGF-1) show promise for osteoarthritis treatment. These IGF-1-ADSCs improved cartilage repair and reduced disease progression in a mouse model.
Area of Science:
- Biomedical Engineering
- Regenerative Medicine
- Stem Cell Therapy
Background:
- Osteoarthritis (OA) is a degenerative joint disease lacking effective disease-modifying therapies.
- Mesenchymal stem cell (MSC) transplantation is promising but faces limitations in efficacy and safety.
- Chemically modified mRNA (modRNA) offers an alternative for enhancing MSC-based OA therapies.
Purpose of the Study:
- To investigate if adipose-derived stem cells (ADSCs) engineered with IGF-1 modRNA (IGF-1-ADSCs) are superior to native ADSCs in treating OA.
- To evaluate the therapeutic potential of IGF-1-ADSCs for cartilage repair and OA management.
Main Methods:
- Mouse ADSCs were transfected with modRNAs encoding insulin-like growth factor 1 (IGF-1).
- In vitro studies assessed modRNA transfection efficiency and the effect of IGF-1-ADSCs on chondrocytes.
- In vivo studies in a murine OA model evaluated IGF-1-ADSC retention and chondroprotective effects using histology and immunohistochemistry.
Main Results:
- High efficiency (85%) modRNA transfection was achieved in mouse ADSCs, leading to significant IGF-1 protein production.
- IGF-1-ADSCs enhanced anabolic markers in chondrocytes under inflammatory conditions.
- In vivo, IGF-1-ADSCs demonstrated superior therapeutic effects in a murine OA model, indicated by lower OARSI scores and reduced cartilage ECM loss.
Conclusions:
- IGF-1-ADSCs exhibit significant therapeutic potential for osteoarthritis management.
- This approach supports the clinical translation of gene-enhanced stem cell therapy for cartilage repair.
